263 related articles for article (PubMed ID: 23783007)
1. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
Bellino S; Paradiso E; Bozzatello P; Bogetto F
J Psychopharmacol; 2010 Mar; 24(3):333-9. PubMed ID: 18719047
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine for premenstrual dysphoric disorder: a pilot study.
Mazza M; Harnic D; Catalano V; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Mar; 9(4):517-21. PubMed ID: 18312154
[TBL] [Abstract][Full Text] [Related]
6. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
7. Effects of adjunctive reboxetine in patients with duloxetine-resistant depression: a 12-week prospective study.
Seguí J; López-Muñoz F; Alamo C; Camarasa X; García-García P; Pardo A
J Psychopharmacol; 2010 Aug; 24(8):1201-7. PubMed ID: 19282423
[TBL] [Abstract][Full Text] [Related]
8. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
9. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
10. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
11. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
Trivedi MH; Desaiah D; Ossanna MJ; Pritchett YL; Brannan SK; Detke MJ
Int Clin Psychopharmacol; 2008 May; 23(3):161-9. PubMed ID: 18408530
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder.
Brecht S; Kajdasz D; Ball S; Thase ME
Int Clin Psychopharmacol; 2008 Nov; 23(6):317-24. PubMed ID: 18854719
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in the long-term treatment of major depressive disorder.
Raskin J; Goldstein DJ; Mallinckrodt CH; Ferguson MB
J Clin Psychiatry; 2003 Oct; 64(10):1237-44. PubMed ID: 14658974
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine pharmacology: profile of a dual monoamine modulator.
Karpa KD; Cavanaugh JE; Lakoski JM
CNS Drug Rev; 2002; 8(4):361-76. PubMed ID: 12481192
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder.
Schatzberg AF
J Clin Psychiatry; 2003; 64 Suppl 13():30-7. PubMed ID: 14552654
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.
Millard RJ; Moore K; Rencken R; Yalcin I; Bump RC;
BJU Int; 2004 Feb; 93(3):311-8. PubMed ID: 14764128
[TBL] [Abstract][Full Text] [Related]
18. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
Bech P; Kajdasz DK; Porsdal V
Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine: a new selective and dual-acting antidepressant.
Bauer M; Möller HJ; Schneider E
Expert Opin Pharmacother; 2006 Mar; 7(4):421-7. PubMed ID: 16503814
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in military posttraumatic stress disorder.
Villarreal G; Cañive JM; Calais LA; Toney G; Smith AK
Psychopharmacol Bull; 2010; 43(3):26-34. PubMed ID: 21150844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]